Inappropriate polypharmacy—the excessive or unnecessary use of multiple medications—is a major driver of emergency hospital ...

As the last nameplate standing from the legacy Bed Bath & Beyond empire, this brand occupies an ill-defined niche in the ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

In his first term, Trump made a lot of noise about lowering drug prices but accomplished little of consequence. The noise continues, but it is now accompanied by new ill-conceived initiatives, ...

Employees enrolled in HDHPs are often the most exposed to price volatility, making pharmacy strategy a critical lever in any ...

Proponents say direct-to-consumer sales by drugmakers cut out intermediaries that add needlessly to prices. Detractors see ethical issues and prices that are still too high for many patients.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

These three tech giants in Cuban's portfolio are still long-term plays despite incredible gains in the past several years.

A new feature added to the state’s All Payer Claims Database lets users compare average prescription costs, helping avoid ...

As federal lawmakers continue to debate major reforms to Medicaid spending, entrepreneur Mark Cuban is proposing what he believes is “the best way to reduce the cost of Medicaid.” In a June 26 post on ...

Is the cost of research aimed at curing HIV worth it, when HIV can be effectively managed and prevented by existing drugs?

For instance, Wan et al found that pembrolizumab plus standard chemotherapy for NSCLC was not cost-effective from the perspectives of US and Chinese payers. 16 Similar conclusions were drawn for other ...